DYN Dyne Therapeutics

Dyne Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference

Dyne Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference

WALTHAM, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- . (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at Chardan’s 6th Annual Genetic Medicines Conference being held in New York, NY on Tuesday, October 4, 2022 at 8:00 a.m. ET.

A live webcast will be available in the Investors & Media section of Dyne’s website at and a replay will be accessible for 90 days following the presentation.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue seen with other approaches. Dyne has a broad portfolio of programs for serious muscle diseases, including candidates for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit , and follow us on ,  and .

Contact:

Dyne Therapeutics

Amy Reilly



857-341-1203



EN
27/09/2022

Underlying

DYNDyne Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Dyne Therapeutics

 PRESS RELEASE
Free
DYN Dyne Therapeuti...

Dyne Therapeutics Announces Participation at 2026 Academy of Managed C...

Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines - Poster on previously shared positive results from DELIVER clinical trial in Duchenne muscular dystrophy (DMD) contextualizes observed clinical measures of functional improvement for managed care experts - - Two posters on myotonic dystrophy type 1 (DM1) focus on health insurance literacy and encore data from ACHIEVE clinical trial - WALTHAM, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: DYN), a clinical-stage com...

April 1, 2026 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 43.35
CMCSA Comcast Corpora...
AMN AMN Healthcare ... ... (+38)

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

CMCSA COMCAST CORPORATION CLASS A
AMN AMN HEALTHCARE SERVICES INC.
TMUS T-MOBILE US INC.
VKTX VIKING THERAPEUTICS
PG PROCTER & GAMBLE COMPANY
MKTX MARKETAXESS HOLDINGS INC.
MCS MARCUS CORPORATION
KURA KURA ONCOLOGY INC.
HUN HUNTSMAN CORPORATION
FFIV F5 NETWORKS INC.
EMN EASTMAN CHEMICAL COMPANY
EDIT EDITAS MEDICINE INC.
CALM CAL-MAINE FOODS INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AWR AMERICAN STATES WATER COMPANY
FF FUTUREFUEL CORP.
JW.A JOHN WILEY & SONS INC. CLASS A
ENPH ENPHASE ENERGY INC.
PRAA PRA GROUP INC.
MLR MILLER INDUSTRIES INC.
PMTS CPI CARD GROUP
RCKT ROCKET PHARMACEUTICALS
KDP KEURIG DR PEPPER INC.
TW TRADEWEB MARKETS INC. CLASS A
NET CLOUDFLARE INC CLASS A
CZR CAESARS ENTERTAINMENT INC
DYN DYNE THERAPEUTICS
RELY REMITLY GLOBAL INC
VTEX VTEX
PFHC PROFRAC HLDG CORP
CAVA CAVA GROUP INC
AESI NEW ATLAS HOLDCO INC
KEI KOLIBRI GLOBAL ENERGY INC
RNAC CARTESIAN THERAPEUTICS INC
NEXN NEXXEN INTERNATIONAL LTD
STRZ STARZ ENTERTAINMENT CORP
ATOM 21SHARES COSMOS ETP
GRND TIGA ACQUISITION CORP
03/12/26 March 12, 2026 1 EN
 PRESS RELEASE
Free
DYN Dyne Therapeuti...

Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-...

Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) - HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for enrollment - - Primary endpoint is the five times sit to stand (5xSTS) test; secondary and exploratory endpoints will assess muscle function, CNS manifestations, and patient- and clinician-reported outcomes - - HARMONIA trial design and protocol aligned with FDA; trial intended to ser...

March 8, 2026 1 EN
 PRESS RELEASE
Free
DYN Dyne Therapeuti...

Dyne Therapeutics Announces New Positive Cardiopulmonary Results from ...

Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) - New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history - - Data expand on previously reported results demonstrating that z-rostudirsen treatment led to sustained functional improvement across multiple clinical measures - WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) -- . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people livin...

March 8, 2026 1 EN
 PRESS RELEASE
Free
DYN Dyne Therapeuti...

Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ...

Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - Planned submission for U.S. Accelerated Approval of z-rostudirsen on track for Q2 2026; potential launch in Q1 2027 - - Positive topline results reported from Phase 1/2 DELIVER trial of z-rostudirsen in exon 51 skip amenable Duchenne muscular dystrophy (DMD); additional long-term data to be presented at MDA - - Completion of enrollment in registrational expansion cohort of Phase 1/2 ACHIEVE trial of z-basivarsen in myotonic dystrophy type 1 (DM1) expected in Q2 2026; Phase 3 tria...

March 2, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch